Keefe, R., Woods, S., Cannon, T., Ruhrmann, S., Mathalon, D., McGuire, P., … Sand, M. (2017). 868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. In Biological Psychiatry (Vol. 81, pp. S351–S351). Elsevier BV. https://doi.org/10.1016/j.biopsych.2017.02.593

Keefe, Richard, Scott Woods, Tyrone Cannon, Stephan Ruhrmann, Daniel Mathalon, Philip McGuire, Gwenaëlle Fillon, Holger Rosenbrock, and Michael Sand. “868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306.” In Biological Psychiatry, 81:S351–S351. Elsevier BV, 2017. https://doi.org/10.1016/j.biopsych.2017.02.593.

Keefe R, Woods S, Cannon T, Ruhrmann S, Mathalon D, McGuire P, et al. 868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. In: Biological Psychiatry. Elsevier BV; 2017. p. S351–S351.

Keefe, Richard, et al. “868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306.” Biological Psychiatry, vol. 81, no. 10, Elsevier BV, 2017, pp. S351–S351. Crossref, doi:10.1016/j.biopsych.2017.02.593.

Keefe R, Woods S, Cannon T, Ruhrmann S, Mathalon D, McGuire P, Fillon G, Rosenbrock H, Sand M. 868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. Biological Psychiatry. Elsevier BV; 2017. p. S351–S351.